Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine in HPV16+ CIN2/3
NCT00121173Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2003
- Primary completion
- Jan 2010
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of pNGVL4a-Sig/E7(detox)/HSP70 in cervical intraepithelial neoplasia (CIN) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Safety and Toxicity at 5 years and Effect on Histology of Cervical Tissue at 15 weeks. Started Nov 2003; status: completed.
02
Drugs
pNGVL4a-Sig/E7(detox)/HSP70
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT00121173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121173.